About: Antiphospholipid antibodies in patients with COVID‐19: a relevant observation?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antiphospholipid antibodies in patients with COVID‐19: a relevant observation? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antiphospholipid antibodies in patients with COVID‐19: a relevant observation?
Creator	Benoit, Dominique Devreese, Katrien Linskens, Eleni Peperstraete, Harlinde
Source	Medline; PMC
abstract	BACKGROUND: High incidence of thrombosis in COVID‐19 patients indicates a hypercoagulable state. Hence, exploring the involvement of antiphospholipid antibodies (aPL) in these patients is of interest. OBJECTIVES: To illustrate the incidence of criteria (lupus anticoagulant (LAC), anticardiolipin (aCL) IgG/IgM, antibeta2‐glycoprotein I antibodies (aβ2GPI) IgG/IgM) and non‐criteria (anti‐prothrombin/phosphatidyl serine (aPS/PT), aCL and aβ2GPI IgA) aPL in a consecutive cohort of critically ill SARS‐CoV‐2 patients, their association with thrombosis, antibody profile and titers of aPL. PATIENTS/METHODS: Thirty one consecutive confirmed COVID‐19 patients admitted to the Intensive Care Unit were included. aPL were measured at one time point, with part of the aPL positive patients retested after one month. RESULTS: Sixteen patients were single LAC positive, two triple positive, one double positive, one single aCL and three aCL IgG and LAC positive. Seven out of 9 thrombotic patients had at least one aPL. 16 out of 22 patients without thrombosis were aPL positive, amongst them two triple positives. Nine out of ten retested LAC positive patients were negative on a second occasion, as well as the double positive patient. Seven patients were aPS/PT positive associated to LAC. Three patients were aCL and aβ2GPI IgA positive. CONCLUSION: Our observations support the frequent single LAC positivity during (acute phase) observed in COVID‐19 infection, however not clearly related to thrombotic complications. Triple aPL positivity and high aCL/aβ2GPI titers are rare. Repeat testing suggests aPL to be mostly transient. Further studies and international registration of aPL should improve understanding the role of aPL in thrombotic COVID‐19 patients.
has issue date	2020-07-03(xsd:dateTime)
bibo:doi	10.1111/jth.14994
bibo:pmid	32619328
has license	no-cc
sha1sum (hex)	fe3ca94d4ce8423a3536ab12fb0c1467e3b82e34
schema:url	https://doi.org/10.1111/jth.14994
resource representing a document's title	Antiphospholipid antibodies in patients with COVID‐19: a relevant observation?
has PubMed Central identifier	PMC7361253
has PubMed identifier	32619328
schema:publication	J Thromb Haemost
resource representing a document's body	covid:fe3ca94d4ce8423a3536ab12fb0c1467e3b82e34#body_text
is schema:about of	named entity 'patients' named entity 'phase' named entity 'aCL' named entity 'frequent' named entity 'phosphatidyl serine' named entity 'positive' named entity '28A' named entity 'SEVEN' named entity 'TIME POINT' named entity 'INVOLVEMENT' named entity 'THROMBOTIC' covid:arg/fe3ca94d4ce8423a3536ab12fb0c1467e3b82e34 named entity 'exploring' named entity 'confirmed' named entity 'Our' named entity 'patients' named entity 'studies' named entity 'observed' named entity 'positive' named entity 'patients' named entity 'positivity' named entity 'Seven' named entity 'measured' named entity 'IgG' named entity 'thrombosis' named entity 'anticoagulant' named entity 'double' named entity 'high' named entity 'profile' named entity 'Objectives' named entity 'negative' named entity 'patient' named entity 'patients' named entity 'rare' named entity 'thrombosis' named entity 'antibodies' named entity 'thrombotic' named entity 'aPL' named entity 'antibody' named entity 'aPL' named entity 'aPL' named entity 'SARS-CoV-2' named entity 'lupus anticoagulant' named entity 'COVID-19' named entity 'prothrombin' named entity 'critically ill' named entity 'acute phase' named entity 'IgG' named entity 'IgA' named entity 'LMWH' named entity 'aCL' named entity 'IgG' named entity 'thrombosis' named entity 'IgG' named entity 'IgM' named entity 'thrombosis' named entity 'intensive care unit' named entity 'titer' named entity 'thrombosis' named entity 'COVID-19' named entity 'IgM' named entity 'false positive' named entity 'Extracorporeal Membrane oxygenation' named entity 'COVID' named entity 'thrombosis' named entity 'March 11' named entity 'aPTT' named entity 'misdiagnosis' named entity 'false positive' named entity 'chromogenic' named entity 'ischemic' named entity 'anticoagulated' named entity 'isotype' named entity 'thrombotic' named entity 'clinical outcome' named entity 'critically ill patients' named entity 'critically ill' named entity 'COVID-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software